These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35568884)

  • 1. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
    Mocanu V; Mackay L; Christie D; Argento E
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):37. PubMed ID: 35568884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
    Carhart-Harris RL; Goodwin GM
    Neuropsychopharmacology; 2017 Oct; 42(11):2105-2113. PubMed ID: 28443617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.
    Holoyda B
    Psychiatr Serv; 2020 Dec; 71(12):1297-1299. PubMed ID: 33050796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.
    Belouin SJ; Averill LA; Henningfield JE; Xenakis SN; Donato I; Grob CS; Berger A; Magar V; Danforth AL; Anderson BT
    Neuropharmacology; 2022 Nov; 219():109214. PubMed ID: 35973601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
    Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M
    J Midwifery Womens Health; 2022 May; 67(3):373-383. PubMed ID: 35522087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 15. The varieties of psychedelic law.
    Marks M
    Neuropharmacology; 2023 Mar; 226():109399. PubMed ID: 36565855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.
    Ortiz CE; Dourron HM; Sweat NW; Garcia-Romeu A; MacCarthy S; Anderson BT; Hendricks PS
    Neuropharmacology; 2022 Aug; 214():109127. PubMed ID: 35577136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for establishing best practices and gold standards in psychedelic medicine.
    Feduccia A; Agin-Liebes G; Price CM; Grinsell N; Paradise S; Rabin DM
    J Affect Disord; 2023 Jul; 332():47-54. PubMed ID: 37003433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policy in focus: Is psilocybin the next cannabis?
    Basky G
    CMAJ; 2021 Nov; 193(45):E1741-E1742. PubMed ID: 34782381
    [No Abstract]   [Full Text] [Related]  

  • 20. Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.
    Horton DM; Morrison B; Schmidt J
    Am J Psychother; 2021 Dec; 74(4):140-149. PubMed ID: 34293927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.